Clinical trials · Massachusetts
Glioblastoma clinical trials in Massachusetts
We’re tracking 27 recruiting glioblastoma studies with a site in Massachusetts — including Early Phase 1, Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT06283927Recruiting
Surgery vs. medical care for recurrent glioblastoma
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
Boston, MassachusettsAges 18–90 - NCT06146725Recruiting
Resection vs. biopsy in high-grade glioma patients
This study compares whether having surgery to remove as much of the tumor as possible (resection) or just taking a small sample (biopsy) leads to better outcomes for people with a fast-growing brain tumor (high-grade glioma). The goal is to help guide treatment decisions.
Boston, MassachusettsAges 18–90 - NCT06273176Recruiting
Surgery with or without brain mapping for recurrent glioblastoma
This study is testing whether using a special brain-mapping technique during surgery helps people with recurrent glioblastoma. It compares standard surgery to surgery with mapping to see if it leads to better outcomes for tumors near important brain areas.
Boston, MassachusettsAges Up to 90 years - NCT06118723Recruiting
Supramaximal vs maximal surgery for brain tumors
This trial compares removing as much tumor as safely possible (supramaximal resection) with standard maximal resection in people with high-grade glioma (an aggressive brain tumor). The goal is to see if more extensive removal improves survival and quality of life.
Boston, MassachusettsAges 18–90 - NCT06146738Recruiting
Palliative care vs. surgery for high-grade glioma patients
This study compares receiving palliative care (supportive treatments) versus surgery (removing the tumor) for people with a high-grade glioma, a fast-growing brain tumor. The goal is to find out which approach improves quality of life and survival.
Boston, MassachusettsAges 18–90 - NCT06649851RecruitingPhase 2
G-CSF to reduce side effects during glioblastoma treatment
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Boston, MassachusettsAges 18 years+ - NCT05660369RecruitingPhase 1
CAR T-cell treatment for EGFR-mutant glioblastoma
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Boston, MassachusettsAges 18 years+ - NCT06552260RecruitingEarly Phase 1
Troriluzole before surgery for recurrent glioblastoma
This trial tests whether an investigational drug called troriluzole can help people with recurrent glioblastoma (a type of brain tumor). You would take the drug for a short time before your planned surgery, so researchers can study how the drug affects your tumor tissue. The goal is to see if it might slow tumor growth.
Boston, MassachusettsAges 18 years+ - NCT06917885RecruitingPhase 1
CUE-102 for Recurrent Glioblastoma: A Safety Study
This study tests an experimental drug, CUE-102, for people with recurrent glioblastoma. It aims to see if the drug is safe and how well it works. You may be eligible if your tumor has come back once, you have a specific genetic marker (HLA-A*0201), and you are not on other treatments.
Boston, MassachusettsAges 18 years+ - NCT06556563RecruitingPhase 3
Optune with chemo and immunotherapy for new glioblastoma
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
Boston, MassachusettsAges 18 years+ - NCT07225621RecruitingPhase 2
Light and sound therapy for newly diagnosed glioblastoma
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
Boston, MassachusettsAges 18–80 - NCT02977780RecruitingPhase 2
Targeted treatment plan for specific glioblastoma tumor markers
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
Boston, MassachusettsAges 18 years+ - NCT03970447RecruitingPhase 2/Phase 3
Testing several treatment options for new or returning glioblastoma
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Boston, MassachusettsAges 18 years+ - NCT04188535Recruiting
MRI scans during radiation treatment
This study does repeated MRI (detailed brain/body imaging) while you receive radiation therapy. It aims to see how these serial scans relate to treatment and outcomes, which could help improve care planning for different cancers.
Boston, MassachusettsAges 18 years+ - NCT04708171Recruiting
Compare awake, asleep, or no mapping during brain tumor surgery
This study looks at whether surgeons get better safety and control during glioblastoma removal by using awake testing, asleep testing, or no mapping. Mapping helps identify brain areas involved in movement, speech, or vision to lower the risk of serious side effects.
Boston, MassachusettsAges 18–90 - NCT05463848RecruitingPhase 2
Surgery plus pembrolizumab with olaparib and temozolomide for glioblastoma
This trial tests a combination treatment after surgery for people with glioblastoma that has come back once or twice. It aims to improve control of the tumor by adding immune therapy and targeted DNA-damage treatment along with chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Boston, MassachusettsAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Boston, MassachusettsAges 1–39 - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Boston, MassachusettsAges 1–21 - NCT06835803RecruitingPhase 2
Intensified radiation for older adults with glioblastoma
This trial tests whether a more focused, stronger dose of radiation can improve outcomes for people 65 and older with newly diagnosed glioblastoma. It compares this approach to standard radiation to see if it's safe and effective.
South Weymouth, MassachusettsAges 65 years+ - NCT06805305RecruitingPhase 2
Immunotherapy for newly diagnosed glioblastoma
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
Boston, MassachusettsAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Boston, MassachusettsAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Worcester, MassachusettsAges Any age
Glioblastoma trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting glioblastoma studies listed above.
- Dana-Farber Cancer Institute · 13 studies
- Massachusetts General Hospital · 13 studies
- Brigham and Women's Hospital · 4 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
- Dana-Farber/Brigham and Women's Cancer Center at South Shore
- Massive Bio SYNERGY-AI site
- Tufts Medical Center
What taking part in a glioblastoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Glioblastoma trials in other states
Common questions
- Are there glioblastoma clinical trials in Massachusetts?
- Yes. We're currently tracking 27 recruiting glioblastoma studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioblastoma study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioblastoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioblastoma studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.